{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T12:55:57Z","timestamp":1782132957609,"version":"3.54.5"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Paroxysmal nocturnal hemoglobinuria (PNH) in children is uncommon and often diagnosed late, particularly in resource-limited settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We report our experience with eight Egyptian children diagnosed between 2018 and 2025, highlighting their clinical course and our initial use of ravulizumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The mean age at diagnosis was 12.6\u2009\u00b1\u20092.8 years, and the median delay before diagnosis was over 1 year. Six patients presented with classic PNH one of whom later evolved to hypocellularity while two demonstrated aplastic anemia -PNH overlap. All presented with severe anemia (mean hemoglobin 6.1\u2009\u00b1\u20090.9\u2009g\/dL), and most had additional cytopenias and biochemical evidence of hemolysis. The disease burden was substantial: thrombotic events, hypertension, and renal involvement were observed during follow-up. Mortality was high; one child died after stem cell transplantation due to acute graft-versus-host disease, and four others, including those with concomitant aplastic anemia died before transplantation could be performed. In contrast, the two patients who received ravulizumab showed rapid clinical and hematologic improvement, became transfusion independent, and experienced only transient adverse effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings underscore the severity of pediatric PNH and highlight the critical importance of timely diagnosis and access to complement inhibition therapy. Ravulizumab demonstrated clear clinical efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Impact<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>Pediatric paroxysmal nocturnal hemoglobinuria (PNH) in Egypt is associated with delayed diagnosis, severe cytopenias, and high early mortality.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>This study provides rare real-world data from a resource-limited setting with limited access to complement inhibition therapy.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Early experience with ravulizumab demonstrated rapid hematologic improvement and transfusion independence.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Improving early recognition and access to targeted therapy may reduce morbidity and mortality in affected children.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41390-026-05202-1","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T12:42:21Z","timestamp":1782132141000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical characteristics and outcomes of pediatric paroxysmal nocturnal hemoglobinuria in Egypt: a real-world cohort study including ravulizumab"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9054-0662","authenticated-orcid":false,"given":"Mervat A. M.","family":"Youssef","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa M.","family":"Embaby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Endi Mohmad","family":"Rashad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad Fathi","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nourhan","family":"Eladghm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enass Mohmed","family":"Said","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"5202_CR1","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/BF00320547","volume":"45","author":"JC Wilmanns","year":"1982","unstructured":"Wilmanns, J. C. Paroxysmal nocturnal hemoglobinuria first described in 1882 by Paul Str\u00fcbing: an example of cooperation between clinical and basic research. Blut 45, 367\u2013373 (1982).","journal-title":"Blut"},{"key":"5202_CR2","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/0092-8674(93)90250-T","volume":"73","author":"J Takeda","year":"1993","unstructured":"Takeda, J. et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell 73, 703\u2013711 (1993).","journal-title":"Cell"},{"key":"5202_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev.med.47.1.1","volume":"47","author":"T Kinoshita","year":"1996","unstructured":"Kinoshita, T., Inoue, N. & Takeda, J. Role of phosphatidylinositol-linked proteins in paroxysmal nocturnal hemoglobinuria pathogenesis. Annu. Rev. Med. 47, 1\u201310 (1996).","journal-title":"Annu. Rev. Med."},{"key":"5202_CR4","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1182\/blood.V86.9.3277.bloodjournal8693277","volume":"86","author":"WF Rosse","year":"1995","unstructured":"Rosse, W. F. & Ware, R. E. The molecular basis of paroxysmal nocturnal hemoglobinuria. Blood 86, 3277\u20133286 (1995).","journal-title":"Blood"},{"key":"5202_CR5","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1056\/NEJM199511093331904","volume":"333","author":"P Hillmen","year":"1995","unstructured":"Hillmen, P., Lewis, S. M., Bessler, M., Luzzatto, L. & Dacie, J. V. l. Natural history of paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. 333, 1253\u20131258 (1995).","journal-title":"N. Engl. J. Med."},{"key":"5202_CR6","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1056\/NEJM199110033251403","volume":"325","author":"RE Ware","year":"1991","unstructured":"Ware, R. E., Hall, S. E. & Rosse, W. F. Paroxysmal nocturnal hemoglobinuria with onset in childhood and adolescence. N. Engl. J. Med. 325, 991\u2013996 (1991).","journal-title":"N. Engl. J. Med."},{"key":"5202_CR7","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/01.md.0000126763.68170.46","volume":"83","author":"JI Nishimura","year":"2004","unstructured":"Nishimura, J. I. et al. Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine 83, 193\u2013207 (2004).","journal-title":"Medicine"},{"key":"5202_CR8","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1111\/j.1365-2141.2004.05337.x","volume":"128","author":"MM van den Heuvel-Eibrink","year":"2005","unstructured":"van den Heuvel-Eibrink, M. M. et al. Childhood paroxysmal nocturnal haemoglobinuria: a report of 11 cases. Br. J. Haematol. 128, 571\u2013577 (2005).","journal-title":"Br. J. Haematol."},{"key":"5202_CR9","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1182\/asheducation-2016.1.208","volume":"2016","author":"CJ Parker","year":"2016","unstructured":"Parker, C. J. Update on the diagnosis and management of paroxysmal nocturnal hemoglobinuria. Hematol. Am. Soc. Hematol. Educ. Program 2016, 208\u2013216 (2016).","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"5202_CR10","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/cyto.b.20525","volume":"78","author":"MJ Borowitz","year":"2010","unstructured":"Borowitz, M. J. et al. Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry. Cytom. B Clin. Cytom. 78, 211\u2013230 (2010).","journal-title":"Cytom. B Clin. Cytom."},{"key":"5202_CR11","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/cyto.b.21023","volume":"82","author":"DR Sutherland","year":"2012","unstructured":"Sutherland, D. R., Keeney, M. & Illingworth, A. Practical guidelines for the high-sensitivity detection and monitoring of paroxysmal nocturnal hemoglobinuria clones by flow cytometry. Cytom. B Clin. Cytom. 82, 195\u2013208 (2012).","journal-title":"Cytom. B Clin. Cytom."},{"key":"5202_CR12","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1056\/NEJMoa061648","volume":"355","author":"P Hillmen","year":"2006","unstructured":"Hillmen, P. et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. 355, 1233\u20131243 (2006).","journal-title":"N. Engl. J. Med."},{"key":"5202_CR13","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.3324\/haematol.2012.062828","volume":"97","author":"RP de Latour","year":"2012","unstructured":"de Latour, R. P. et al. Allogeneic stem cell transplantation in paroxysmal nocturnal hemoglobinuria. Haematologica 97, 1666\u20131673 (2012).","journal-title":"Haematologica"},{"key":"5202_CR14","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1182\/blood-2014-03-560540","volume":"125","author":"R Peffault de Latour","year":"2015","unstructured":"Peffault de Latour, R. et al. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. Blood 125, 775\u2013783 (2015).","journal-title":"Blood"},{"key":"5202_CR15","doi-asserted-by":"publisher","first-page":"e344","DOI":"10.1016\/S2352-3026(21)00028-4","volume":"8","author":"AM Risitano","year":"2021","unstructured":"Risitano, A. M. et al. Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis. Lancet Haematol. 8, e344\u2013e354 (2021).","journal-title":"Lancet Haematol."},{"key":"5202_CR16","first-page":"3756","volume":"4","author":"JH Jang","year":"2020","unstructured":"Jang, J. H. et al. Ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b\/2 studies. Blood Adv. 4, 3756\u20133766 (2020). 2020.","journal-title":"Blood Adv."},{"key":"5202_CR17","doi-asserted-by":"publisher","first-page":"4985","DOI":"10.1182\/blood-2012-09-311381","volume":"121","author":"A Hill","year":"2013","unstructured":"Hill, A., Kelly, R. J. & Hillmen, P. Thrombosis in paroxysmal nocturnal hemoglobinuria. Blood 121, 4985\u20134996 (2013).","journal-title":"Blood"},{"key":"5202_CR18","doi-asserted-by":"publisher","first-page":"922","DOI":"10.3324\/haematol.2013.093161","volume":"99","author":"H Schrezenmeier","year":"2014","unstructured":"Schrezenmeier, H. et al. Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry. Haematologica 99, 922\u2013929 (2014).","journal-title":"Haematologica"},{"key":"5202_CR19","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1182\/bloodadvances.2023012267","volume":"8","author":"S Chonat","year":"2024","unstructured":"Chonat, S. et al. Pharmacokinetics, pharmacodynamic, efficacy, and safty of Ravulizumab in pediatric. Blood Adv. 8, 2813\u20132824 (2024).","journal-title":"Blood Adv."},{"key":"5202_CR20","unstructured":"Alexion Pharmaceuticals, Inc. Alexion announces FDA approval of ULTOMIRIS\u00ae (ravulizumab-cwvz) for children and adolescents with Paroxysmal Nocturnal Hemoglobinuria (PNH). Business Wire. June 7, 2021. Accessed June 11, 2026. https:\/\/www.businesswire.com\/news\/home\/20210607005638\/en\/."},{"key":"5202_CR21","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1182\/blood.2019003812","volume":"137","author":"RA Brodsky","year":"2021","unstructured":"Brodsky, R. A. How I treat paroxysmal nocturnal hemoglobinuria. Blood 137, 1304\u20131309 (2021).","journal-title":"Blood"},{"key":"5202_CR22","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/ejh.13176","volume":"102","author":"CJ Patriquin","year":"2019","unstructured":"Patriquin, C. J. et al. How we treat paroxysmal nocturnal hemoglobinuria: a consensus statement of the Canadian PNH Network and review of the national registry. Eur. J. Haematol. 102, 36\u201352 (2019).","journal-title":"Eur. J. Haematol."},{"key":"5202_CR23","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1056\/NEJM198203183061105","volume":"306","author":"BM Camitta","year":"1982","unstructured":"Camitta, B. M., Storb, R. & Thomas, E. D. Aplastic anemia (first of two parts): pathogenesis, diagnosis, treatment, and prognosis. N. Engl. J. Med. 306, 645\u2013652 (1982).","journal-title":"N. Engl. J. Med."},{"key":"5202_CR24","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1056\/NEJM198203253061204","volume":"306","author":"BM Camitta","year":"1982","unstructured":"Camitta, B. M., Storb, R. & Thomas, E. D. Aplastic anemia (second of two parts): pathogenesis, diagnosis, treatment, and prognosis. N. Engl. J. Med. 306, 712\u2013718 (1982).","journal-title":"N. Engl. J. Med."},{"key":"5202_CR25","doi-asserted-by":"publisher","first-page":"e76","DOI":"10.3324\/haematol.2016.151852","volume":"102","author":"\u00c1 Urbano-Ispizua","year":"2016","unstructured":"Urbano-Ispizua, \u00c1 et al. Different clinical characteristics of paroxysmal nocturnal hemoglobinuria in pediatric and adult patients. Haematologica. 102, e76\u2013e79 (2016).","journal-title":"Haematologica"},{"key":"5202_CR26","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.bcmd.2017.03.006","volume":"64","author":"A Mercuri","year":"2017","unstructured":"Mercuri, A. et al. A retrospective study of paroxysmal nocturnal hemoglobinuria in pediatric and adolescent patients. Blood Cells Mol. Dis. 64, 45\u201350 (2017).","journal-title":"Blood Cells Mol. Dis."},{"key":"5202_CR27","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s12288-017-0868-y","volume":"33","author":"P Manivannan","year":"2017","unstructured":"Manivannan, P., Ahuja, A. & Prasad Pati, H. Diagnosis of paroxysmal nocturnal hemoglobinuria: recent advances. Indian J. Hematol. Blood Transfus. 33, 453\u2013462 (2017).","journal-title":"Indian J. Hematol. Blood Transfus."},{"key":"5202_CR28","doi-asserted-by":"crossref","unstructured":"Moon, J. Y. et al. Low-dose prednisolone in patients with paroxysmal nocturnal hemoglobinuria and inadequate response to eculizumab. Blood Res. 52, 337\u2013339 (2017).","DOI":"10.5045\/br.2017.52.4.337"},{"key":"5202_CR29","doi-asserted-by":"crossref","unstructured":"Brodsky, R. A. (2009). How I treat paroxysmal nocturnal hemoglobinuria. Blood 113, 6522\u20136527.","DOI":"10.1182\/blood-2009-03-195966"},{"key":"5202_CR30","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1182\/bloodadvances.2023012267","volume":"8","author":"S Chonat","year":"2024","unstructured":"Chonat, S. et al. Pharmacokinetics, pharmacodynamics, efficacy, and safety of ravulizumab in pediatric paroxysmal nocturnal hemoglobinuria. Blood Adv. 8, 2813\u20132824 (2024).","journal-title":"Blood Adv."},{"key":"5202_CR31","doi-asserted-by":"publisher","first-page":"6786","DOI":"10.1182\/blood-2011-02-333997","volume":"117","author":"RJ Kelly","year":"2011","unstructured":"Kelly, R. J. et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood 117, 6786\u20136792 (2011).","journal-title":"Blood"}],"container-title":["Pediatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-05202-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-05202-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-05202-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T12:42:29Z","timestamp":1782132149000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-05202-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":31,"alternative-id":["5202"],"URL":"https:\/\/doi.org\/10.1038\/s41390-026-05202-1","relation":{},"ISSN":["0031-3998","1530-0447"],"issn-type":[{"value":"0031-3998","type":"print"},{"value":"1530-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"assertion":[{"value":"4 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}